C-Reactive Protein (CRP) Testing Market Overview

The global C-reactive protein (CRP) testing market is anticipated to witness steady growth from 2025 to 2033, driven by the rising prevalence of chronic inflammatory diseases, infections, and cardiovascular conditions. The market is expected to be valued at USD 3.1 billion in 2025 and projected to reach USD 5.8 billion by 2033, growing at a CAGR of 8.2% during the forecast period.

CRP tests are essential diagnostic tools used to detect inflammation and monitor disease progression. They help in the early detection of conditions such as sepsis, rheumatoid arthritis, and heart disease. Growing demand for point-of-care (POC) testing and increasing use of high-sensitivity CRP (hs-CRP) for cardiovascular risk stratification are key contributors to market expansion.

Advancements in immunoassay technologies, automation in diagnostics, and rising awareness of preventive healthcare are further fuelling adoption. Moreover, CRP testing is becoming integral in managing post-operative inflammation, infections, and COVID-19-related complications, enhancing its clinical relevance.

Drivers, Restraints, and Opportunities for C-reactive Protein (CRP) Testing Market

Rising Incidence of Chronic and Inflammatory Diseases

The market is being significantly driven by the increasing global burden of chronic diseases such as cardiovascular conditions, rheumatoid arthritis, and diabetes—all of which involve systemic inflammation. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for over 17.9 million deaths annually. CRP tests are widely used to monitor disease progression and treatment efficacy. The high-sensitivity CRP (hs-CRP) test is especially useful in cardiovascular risk prediction. As aging populations grow in both developed and developing countries, the need for accurate, cost-effective, and rapid diagnostics to assess inflammatory markers like CRP is intensifying. This growing demand is encouraging diagnostic companies to expand their test portfolios and develop point-of-care CRP testing platforms.

Expansion of Point-of-Care and Home Testing Solutions

The transition toward decentralized healthcare is opening up opportunities for point-of-care CRP testing. These portable and rapid diagnostic tests are ideal for use in outpatient settings, remote areas, and even home care, offering fast turnaround times and better disease management. Manufacturers are increasingly focusing on developing user-friendly, automated CRP testing kits compatible with smartphones and portable devices. The pandemic accelerated the adoption of such tools, and many healthcare providers now prefer CRP tests as part of broader infection screening. The growing trend toward personalized medicine and telehealth further supports the demand for on-the-spot CRP monitoring devices.

Opportunity: Integration with AI and Predictive Analytics

The growing integration of artificial intelligence (AI) in diagnostic platforms is enhancing the predictive capability of CRP testing. When combined with other biomarkers and patient health data, CRP levels can offer a deeper understanding of disease progression, particularly in sepsis or cardiovascular risk scoring. Predictive algorithms are helping clinicians make more informed decisions based on CRP dynamics over time. Furthermore, AI can assist in pattern recognition, risk categorization, and treatment optimization, making CRP test data more actionable. Companies investing in cloud-connected diagnostic platforms and digital health ecosystems are likely to unlock new growth frontiers in the CRP testing landscape.

C-Reactive Protein (CRP) Testing Market Scope

C-Reactive Protein (CRP) Testing Market Report Segmentation Analysis

The global C-reactive Protein (CRP) Testing Market industry analysis is segmented by product type, by application, by end-user, and by region.

Immunoturbidimetric Assay Leads Product Segment

The immunoturbidimetric assay dominates the product type segment of the CRP testing market, owing to its simplicity, cost-efficiency, and high throughput capability. It is a preferred choice for routine CRP measurement in both hospitals and diagnostic laboratories, particularly due to its compatibility with automated analyzers. This assay method works by measuring the turbidity formed when CRP in the sample reacts with specific antibodies, offering quick and accurate quantitative results. It is particularly beneficial in high-volume clinical laboratories where rapid turnaround is crucial. Immunoturbidimetric assays are also advantageous due to their reduced reagent consumption and minimal sample preparation requirements. Moreover, this method can be seamlessly integrated into existing clinical chemistry platforms, enhancing operational efficiency. Despite the rise of newer technologies like ELISA and chemiluminescence-based methods, immunoturbidimetric assays continue to lead due to their proven reliability, affordability, and scalability across various healthcare systems, especially in developing markets with limited access to advanced diagnostic infrastructure.

Cardiovascular and Infection Applications Dominate the Market

Cardiovascular disease remains the leading application segment for CRP testing, particularly with the growing clinical emphasis on high-sensitivity CRP (hs-CRP) tests. hs-CRP assays are pivotal in detecting low-grade inflammation that correlates with an elevated risk of heart attacks, strokes, and atherosclerosis, making them essential in preventive cardiology. Simultaneously, CRP testing is increasingly used in infection diagnostics, where elevated CRP levels help differentiate bacterial from viral infections. This has proven especially useful in guiding antibiotic prescriptions, reducing antimicrobial resistance risks. Post-COVID-19, the infection segment has witnessed accelerated growth, as CRP monitoring became integral to managing disease severity and secondary infections. Inflammatory markers like CRP are also valuable in tracking treatment response in sepsis and pneumonia. The rheumatoid arthritis segment maintains strong demand as CRP levels are key in evaluating disease activity and response to biologic therapies. As clinical protocols evolve, CRP testing is likely to see further integration across broader inflammatory and infectious disease management strategies.

Hospitals and Diagnostic Labs Drive Demand

Hospitals hold the largest share in the CRP testing market due to their comprehensive testing capabilities, centralized lab infrastructure, and access to integrated diagnostic platforms. These institutions frequently perform CRP tests as part of routine panels for patient monitoring in emergency, ICU, and cardiology departments. The use of high-sensitivity CRP in cardiovascular risk assessments and monitoring of inflammatory diseases adds to the test’s significance in hospital settings. Electronic health record (EHR) integration in hospitals also enables continuous monitoring of CRP trends, aiding in clinical decision-making. Diagnostic laboratories are rapidly gaining traction owing to their ability to handle large test volumes and offer automated, high-throughput testing solutions. Moreover, the outsourcing of testing services by smaller clinics further bolsters the role of diagnostic labs. Meanwhile, clinics and home care settings represent emerging growth areas, driven by the rise of point-of-care (POC) testing devices. These segments are expanding as healthcare becomes increasingly decentralized and patient-centric, encouraging CRP testing closer to the point of need.

The following segments are part of an in-depth analysis of the global C-reactive Protein (CRP) Testing Market:

C-reactive Protein (CRP) Testing Market Share Analysis by Region

North America to Maintain Market Leadership

North America continues to dominate the global CRP testing market due to advanced healthcare infrastructure, high chronic disease prevalence, and adoption of innovative diagnostic solutions. The U.S. leads with strong investment in hospital-based testing and preventive healthcare programs. Europe is the second-largest market, with widespread use of hs-CRP tests for cardiovascular risk prediction, especially in Germany, the U.K., and France. The Asia-Pacific region is emerging as a high-growth market, driven by expanding healthcare access, aging populations, and growing awareness of early diagnostics in India, China, and Southeast Asia.

Global C-reactive Protein (CRP) Testing Market Recent Developments News:

• In May 2025, Roche Diagnostics introduced a new high-sensitivity CRP point-of-care (POC) device aimed at enhancing cardiovascular risk screening in outpatient and primary care settings. The device offers rapid, lab-quality results in under 10 minutes, supporting early detection of low-grade systemic inflammation—a key marker for cardiovascular events.
• In February 2025, Thermo Fisher Scientific entered into a strategic partnership with the Mayo Clinic to co-develop a suite of AI-driven diagnostic tools that leverage CRP levels and longitudinal patient data for enhanced inflammation diagnostics.
• In November 2024, Abbott Laboratories announced that the U.S. Food and Drug Administration (FDA) had approved its high-sensitivity CRP (hs-CRP) assay for use on the Alinity diagnostic platform. The hs-CRP assay enables clinicians to assess inflammation levels with enhanced precision, particularly for cardiovascular risk evaluation.

The Global C-reactive Protein (CRP) Testing Market is dominated by a few large companies, such as

●        Roche Holding AG

●        Abbott Laboratories

●        Thermo Fisher Scientific

●        Danaher Corporation (Beckman Coulter)

●        Siemens Healthineers

●        Bio-Rad Laboratories

●        Randox Laboratories

●        Becton, Dickinson and Company

●        Merck KGaA

●        Quest Diagnostics

●        Ortho Clinical Diagnostics

●        Getein Biotech

●        Shenzhen Mindray Bio-Medical Electronics

●        Other Emerging Players